The Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination and Infection on Neutralizing Antibodies: A Nation-wide Cross-sectional Analysis.

Autor:	Althaus T; Monaco Health Affairs Directorate, Monaco.; Monaco Scientific Centre, Monaco.; Global Virus Network, Baltimore, USA., Landier J; IRD, Aix Marseille University, INSERM, SESSTIM, Aix Marseille Institute of Public Health, ISSPAM, France., Zhu F; Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore., Raps H; Monaco Scientific Centre, Monaco., Dejoux O; Monaco Scientific Centre, Monaco., Costantini A; Monaco Scientific Centre, Monaco., Lavagna C; Monaco Scientific Centre, Monaco.; Centre Hospitalier Princesse Grace, Monaco., Rampal P; Monaco Scientific Centre, Monaco., Mattiuzzo G; Vaccines (Research and Development), Medicines and Healthcare Products Regulatory Agency, United Kingdom., Xu S; GenScript Biotech, the Netherlands., Wang LF; Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.; SingHealth Duke-NUS Global Health Institute, Singapore., Voiglio EJ; Monaco Health Affairs Directorate, Monaco.
Jazyk:	angličtina
Zdroj:	The Journal of infectious diseases [J Infect Dis] 2023 May 29; Vol. 227 (11), pp. 1255-1265.
DOI:	10.1093/infdis/jiad030
Abstrakt:	Background: Neutralising antibodies (nAbs) play a critical role in the protection against severe COVID-19. In the era of vaccine boosters and repeated SARS-CoV-2 outbreaks, identifying individuals at risk represents a public health priority. Methods: Relying on the Monaco COVID Public Health Programme, we evaluated nAbs from July 2021-June 2022 in 8,080 SARS-CoV-2 vaccinated and/or infected children and adults, at their inclusion visit. We stratified by infection status and investigated variables associated with nAbs using a generalised additive model. Results: Infected and vaccinated participants had high and consistent nAbs (>800 IU/mL), which remained stable over time since injection, regardless of the number of vaccine doses, body mass index, sex, or age. By contrast, uninfected participants showed larger variability (two doses [V2] median 157.6; interquartile range [IQR] 43.3-439.1 IU/mL) versus three doses [V3] median 882.5; [829.5-914.8] IU/mL). NAbs decreased by 20% per month after V2 (adjusted ratio 0.80; 95%CI [0.79-0.82]), but remained stable after V3 (adjusted ratio 0.98; 95%CI [0.92-1.05]). Conclusions: Hybrid immunity provided stable, high and consistent nAbs over time. The benefit of boosters was marked to restore decaying nAbs in uninfected participants. NAbs could identify individuals at risk of severe COVID-19 and provide more targeted vaccine boosters' campaigns. Competing Interests: Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu